Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
1  
 
 
A Prospective, Randomized, Clinical Trial to  Compare Adverse Birth Outcomes in 
Pregnant Women Receiving Quadrivalent Recombinant Influenza Vaccine (RIV4) versus 
Quadrivalent Inactivated Influenza Vaccine (IIV4) 
 
Short Title: Safety of RIV4 versus  IIV4 in Pregnant Women  
 
 
Centers for Disease Control and Prevention  
Clinical Immunization Safety Assessment (CISA) Project  
 
 
Lead Site Principal Investigator: [INVESTIGATOR_213023] K. Swamy , MD  
Lead Site Sub -principal Investigator: [INVESTIGATOR_213024] -Katz, MD , MEd  
 
Contributing Site Principal Investigator: [INVESTIGATOR_213025], MD  
Contributing Site Sub- principal Investigator: [INVESTIGATOR_213026], DO, MS  
 
Contributing Site Principal Investigator: [CONTACT_27429] I. Pelton, MD  
Contributing Site Sub- principal Investigator: [INVESTIGATOR_213027], MD  
 
Centers for Disease Control and Prevention (CDC) Principal Investigator: [CONTACT_19767] R. 
Broder, MD  
CDC Sub -principal Investigator : [INVESTIGATOR_213028] , MD  
  
[STUDY_ID_REMOVED]  
 
Version Number: 4.0  
 
15 Mar 2022  
   
  
  
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
2 STATEMENT OF COMPLIA NCE  
• This trial will be conducted in compliance with the protocol, the International 
Conference on Harmoniz ation (ICH) Guideline E6- Good Clinical Practice (GCP), 
and the applicable guidelines and regulatory requirements from the [LOCATION_002] 
(US) Code of Federal Regulations (CFR), 45 CFR Part 46.  
• All study personnel with subject contact [CONTACT_174855].  
 
  
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
3  
TABLE OF CONTENTS  
 
PROTOCOL SUMMARY  .............................................................................................................................................. 5 
1 BACKGROUND  .................................................................................................................................................. 9 
1.1 BACKGROUND  .................................................................................................................................................................... 9 
1.2 SUMMARY & RATIONALE  ............................................................................................................................................... 10 
2 STUDY OBJECTIVES  ..................................................................................................................................... 10 
2.1 STUDY OUTCOME MEASURES  ........................................................................................................................................ 11 
2.1.1  Primary Outcome Measure:  ........................................................................................................................ 11 
2.1.2  Secondary Outcome Measures:  .................................................................................................................. 11 
2.1.3  Exploratory Outcome Measures:  ............................................................................................................... 11 
3 STUDY DESIGN  ............................................................................................................................................... 12 
3.1 MAIN STUDY DES IGN ....................................................................................................................................................... 12 
3.2 LABORATORY STUDIES .................................................................................................................................................... 12 
3.2.1  Serologic studies  .............................................................................................................................................. 12 
4 STUDY EN ROLLMENT AND WITHDRAWALS  ...................................................................................... 13 
4.1 PARTICIPANT INCLUSION CRITERIA  ............................................................................................................................. 13 
4.2 PARTICIPANT EXCLUSION CRITERIA  ............................................................................................................................ 14 
4.3 RECRUITMENT  ................................................................................................................................................................. 15 
4.4 REASONS FOR AND HANDLING OF WITHDRAWALS  ................................................................................................... 15 
4.5 TERMINATION OF STUDY  ............................................................................................................................................... 15 
5 STUDY SCHEDULE, PROC EDURES, & EVALUATION S ........................................................................ 15 
5.1 SCHEDULE OF EVENTS  .................................................................................................................................................... 15 
5.2 TREATMENT ASSIGNMENT PROCEDURES .................................................................................................................... 20 
5.2.1  Randomization  ................................................................................................................................................. 20 
5.2.2  Blinding  ............................................................................................................................................................... 20 
5.2.3  Vaccine Supp ly, Storage, and Administration ...................................................................................... 20 
5.3 REACTOGENICITY AND SAFETY ASSESSMENTS  ........................................................................................................... 21 
5.4 BIOSPECIMENS COLLECTION & HANDLING  ................................................................................................................. 23 
5.4.1  Serum  ................................................................................................................................................................... 23 
6 LABORATORY ANALYSES  .......................................................................................................................... 24 
6.1 INFLUENZA LABORATORY ANALYSIS  ........................................................................................................................... 24 
7 STATISTICAL CONSIDER ATIONS  ............................................................................................................. 24 
7.1 DEFINITIONS  .................................................................................................................................................................... 24 
7.2 SAMPLE SIZE AND POWER ESTIMATION  ..................................................................................................................... 24 
7.3 ANALYSIS PLAN ............................................................................................................................................................... 25 
7.3.1 Study Popu lations  .................................................................................................................................................. 25 
7.3.2   Alpha Level  ............................................................................................................................................................. 25 
7.3.3   Primary Objective  ................................................................................................................................................ 25 
7.3.4  Secondary Objective 1.  .................................................................................................................................. 26 
7.3.5    Secondary Objective 2  ....................................................................................................................................... 26 
7.3.6    Seconda ry Objective 3  ....................................................................................................................................... 26 
7.3.7    Secondary Objective 4  ....................................................................................................................................... 26 
7.3.8  Exploratory Objective 1  ................................................................................................................................ 26 
7.3.9     Exploratory Objective 2  ................................................................................................................................... 27 
7.3.10  Exploratory Objective 3  .......................................................................................................................... 27 
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
4 7.3.11  Explorat ory Objective 4  .......................................................................................................................... 27 
7.3.12  Exploratory Objective 5  .......................................................................................................................... 27 
7.3.13 Sensitivity analysis  .................................................................................................................................... 27 
7.3.14  Interim Safety Data Review  .................................................................................................................. 28 
7.3.16  Further analysis  ......................................................................................................................................... 28 
7.4 DATA MANAGEMENT PLAN ........................................................................................................................................... 28 
7.4.1 Re search Electronic Data Capture (REDCap)  ............................................................................................. [ADDRESS_255517] Risk  ............................................................................................................................... 31 
8.4.2  ClinicalTrials.gov Requirements  ............................................................................................................... 32 
9.0 HUMAN PARTICIPANTS  .................................................................................................................................................. 32 
9.1.1  Vulnerable Subjects Research  .................................................................................................................... 32 
REFERENCES  ............................................................................................................................................................. 33 
  
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
5 PROTOCOL SUMMARY  
 
Title:  A Prospective, Randomized, Clinical Trial to  Compare Adverse 
Birth Outcomes in Pregnant Women Receiving Quadrivalent 
Recombinant Influenza Vaccine (RIV4) versus Quadrivalent 
Inactivated Influenza Vaccine (IIV4)  
 
Phase:  Phase 4  
Population:  430 adult  pregnant women ≥ 18 years  at ≤ 34 weeks gestation  
who plan on receiving RIV4 or IIV4  during the current pregnancy 
in accordance with the Advisory Committee on Immunization 
Practices (ACIP)  and American College of Obstetricians & 
Gynecologists (ACOG) national recommendations.     
Clinical Sites:  Three: Duke  University (Lead); Cincinnati Children’s Hospi[INVESTIGATOR_139761]  (Contributor) ; [LOCATION_011] Medical Center 
(Contributor)  
Study Duration:  60 months ( approximately 12 months to recruit /enroll ), 
maximum of 24  months to follow, 24 months to perform analysis  
and laboratory assays   
Participa nt Duration:  Up to 12 months  depending upon gestational age at enrollment 
and delivery.  Will be followed for 90 days postpartum.  
Description of Study 
Procedures: This is a prospective, randomized clinical trial . During the 
study, pregnant women will be randomized (1:1) to receive 
RIV4 or IIV4.   Vaccines will be administered by [CONTACT_213039] .   
 
Prior influenza vaccine history will be verified by [CONTACT_213040].  
 Injection- site (local) and systemic reaction data will be 
assessed on vaccination day and during the 8 days following 
vaccination using either identical web- based or paper diaries, 
depending on study participant  preference.  
 Maternal serum samples will be collected for antibody titers 
relevant to Influenza at time points that include: prior to 
vaccination and ~[ADDRESS_255518]  review .   
Objectives : Primary Objectives:  
• To compare the proportions of adverse birth outcomes 
in pregnant women vaccinated with RIV4 versus IIV4   
 Secondary Objectives:  
• To compare proportions of preterm birth after RIV4 
versus IIV4 vaccination  
• To compare proportions of combined fetal and neonatal 
death after RIV4 versus IIV4 vaccination  
• To compare proportions of spontaneous abortion after 
RIV4 versus IIV4 vaccination  
• To compare proportions of moderate/severe solicited 
reactogenicity events in pregnant women vaccinated 
with RIV4 versus IIV4  
 
Exploratory Objectives:  
• To compare and describe serious adverse events 
(SAE) in pregnant women vaccinated with RIV4 versus 
IIV4 
• To compare proportions of adverse pregnancy and birth outcomes of clinical interest after RIV4 versus IIV4 
vaccination  
• To compare and describe health outcomes through 90 
days of life in infants born to women after RIV4 versus 
IIV4 vaccination  
• To compare maternal immune responses to influenza 
antigens after RIV4 versus IIV4 vaccination  
• To compare cord blood antibody levels  for influenza 
antigens after RIV4 versus IIV4 vaccination  
Outcome Measures:  Primary:   
• Proportions of adverse birth outcomes in pregnant 
women vaccinated with RIV4 versus IIV4  
 
Secondary:  
• Proportions of preterm birth after RIV4 versus IIV4 
vaccination  
• Proportions of combined fetal and neonatal death after 
RIV4 versus IIV4 vaccination 
• Proportions of spontaneous abortion after RIV4 versus 
IIV4 vaccination  
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
7 • Proportions of pregnant women with moderate/severe 
solicited reactogenicity events (local and systemic)  
within 8 days after vaccination with RIV4 versus IIV4 
 
Exploratory:  
• Frequency and descriptions of serious adverse events 
in pregnant women vaccinated with RIV4 versus IIV4 
during the 42 days after vaccination  
• Frequency and descriptions of serious adverse events in pregnant women vaccinated with RIV4 versus IIV4 
after vaccination during the 
study  
• Proportions of infants born small for gestational age 
after RIV4 versus IIV4  vaccination 
• Proportion of pregnant women with clinical chorioamnionitis, after RIV4 versus IIV4 vaccination 
• Proportion of women with preeclampsia or eclampsia after RIV4 versus IIV4 vaccination 
• Proportion of infants with medically -attended adverse 
events through 90 days of life after maternal RIV4 
versus IIV4 vaccination 
• Frequency and description of SAEs in infants through 
90 days of life after maternal RIV4 versus IIV4 
vaccination  
• Proportion of infants with neonatal death after maternal 
RIV4 versus IIV4  vaccination 
• Proportion of pregnant women achieving seroconversion at day 29 after RIV4 versus IIV4 
vaccination [ a Hemagglutination Inhibition Assay (HAI) 
titer > 1:40 at day 29  if the baseline titer is < 1:10 or a 
minimum four-fold rise in HAI  titer if the ba seline  titer is 
> 1:10) for each influenza vaccine antigen]  
• Proportion of pregnant women with a seroprotective 
HAI titer (≥ 1:40) post -immunization at day 29 after 
RIV4 versus IIV4  vaccination for each  influenza vaccine 
antigen  
• The maternal geometric mean HAI titer (GMT) pre and 
post-vaccination at day [ADDRESS_255519]/pre -
vaccination ratio  
• Proportion of infants with cord blood seroprotective HAI titer (≥ 1:40) for eac h influenza vaccine antigen after 
maternal RIV4 vers us IIV4 vaccination 
• Infant cord blood geometric mean HAI titer (GMT) for 
each influenza vaccine antigen after maternal RIV4 versus IIV4 vaccination 
• Ratio of cord blood to maternal influenza antibody titers 
at time of delivery for each influenza vaccine antigen 
after maternal RIV4 versus IIV4 vaccination  
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
8 Estimated Time to Complete 
Enrollment:  Approximately [ADDRESS_255520] influenza can 
be associated with adverse birth outcomes such as preterm birth and fetal demise.3  
Complications  of influenza during pregnancy  can be even higher during pandemics, as 
seen in the 2009 H1N1 pandemic  when the preterm birth rate rose threefold among 
infected pregnant women and 5% of all related deaths  reported to CDC  occurred in 
pregnant women, yet they only encompass 1% of the total population.4  The Advisory 
Committee on Immunization Prac tices (ACIP) and the American College of Obstetricians 
& Gynecologists (ACOG) have recommend an age- appropriate inactivated influenza 
vaccine (IIV) for all women who are or  will be pregnant during influenza season.5,[ADDRESS_255521] 
supported the safety and effectiveness of IIV in pregnancy.8-12 
Due to continuous  evolution of influenza glycoproteins, the World Health Organization 
(WHO ) meets to consider and make recommendations  for updates in influenza vaccine 
composition twice a year. For the northern hemisphere, the WHO generally makes these 
recommendations in February.  The U.S. F ood and Drug Administration (F DA) Vaccines 
and Related Biological Products Advisory Committee (VRBPAC) subsequently meets  in 
late February or early March to determine composition of the vaccines to be produced, 
distributed, and administered in the U nited States  starting late summer of the same year. 
Since the 1940s, standard IIV manufacturing has involved the use of embryonated hen 
eggs. While effective, th is technology is hampered by [CONTACT_213041]- free 
eggs and specialized manufacturing facilities in which throughput can only be amplified by [CONTACT_213042]. This process is  also vulnerable to avian influenza 
viruses. Finally, the lengthy production process hinders potential for rapid scale- up in 
response to emerging needs such as a pandemic or supply shortage.  
HHS has supported development of alternate influenza vaccine technology  as a 
component of influenza preparedness .
13 In January 2013 the U .S. FDA approved 
Flublok®, the first recombinant influenza vaccine (RIV) , RIV  contains  influenza virus 
antigens manufactured using an insect baculovirus expression system and recombinant 
technology.  RIV does not contain ovalbumin.  FDA licensed a quadrivalent formulation of 
RIV, Flublok ® Quadrivalent (RIV4) in 2016 .14  RIV may offer some advantages to egg -
based vaccines.  Production time during a pandemic may be shorter, and permit earlier availability of vaccine (though this has not yet been demonstrated).  In addition, it is not 
subject to egg- adaptation mutations that can occur in influenza vaccine virus strains as 
they are passaged through eggs.   Some evidence suggests that such mutations may 
affect vaccine eff ectiveness.
15  However, specific effectiveness data for RI V are currently 
limited  due to its relatively limited use  to date.  
In 2017, ACIP expanded its influenza vaccine recommendation for pregnant women to 
include RIV with no stated preference between RIV and IIV products.6  Data on uptake of 
RIV in pregnant women following the 2017 ACIP recommendations to include this 
vaccine in its maternal influenza recommendations are not available.  Data from CDC’s 
Vaccine Safety Datalink  (VSD) suggest that use of RIV in the adult populat ion has been 
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
10 limited (VSD, unpublished data, 2019 ). However, it is possible that use among pregnant 
women might increase during a pandemic or a season of vaccine shortage,  as RIV might 
be available earlier than other vaccines, and pregnant women are among the 
populations recommended to be a focus  for vaccination efforts when vaccine supply is 
limited . Furthermore, use of RIV may become more widespread in future seasons due to 
concerns about decreased vaccine effectiveness related to egg adaptation.   
 
Altho ugh approved for adults ≥ 18 years, prelicensure studies for RIV specifically 
excluded pregnant women. To date, safety data  on RIV use during pregnancy  are limited  
to manufacturer registry data, regulatory  data that describes incidental pregnancies that 
occurred during the course of clinical trials , and passive surveillance data, including  data 
obtained from a large influenza vaccination campaign in Mongolia.6 These data are  
reassuring, with no indication of adverse reactogenicity or obstetric events. While the 
Vaccine Adverse Event Reporting System (VAERS) can provide information on safety of 
licensed vaccines , there are inherent limitations of this passive surveillance system . In 
the VSD, the number of RIV doses administered to pregnant women is expected to be 
insufficient for comparative studies. ACIP stated during their June [ADDRESS_255522] influenza illness  in pregnant is also 
important. Given the obligatory changes in maternal immunology to allow for fetal 
tolerance, the immunogenicity of RIV during pregnancy should also be assessed.  
1.2 Summary & Rationale  
ACIP currently recommends that pregnant women aged ≥  18 years receive an age -
appropriate IIV or RIV (Flublok ® Quadrivalent . While there is no specific reason to 
expect RIV to be unsafe during pregnancy,  the lack of systematically collected data on 
the safety of RIV in pregnancy places  a burden on obstetric providers and pregnant 
women to assess risk -benefit balance in the  context of limited data. Establishing the 
safety of RIV is imperative to support current use among pregnant women during 
seasonal vaccination efforts and in the event that RIV is widely used during a pandemic 
or supply shortage when pregnant women may be  prioritized for vaccination. 
Systematically collected data from a rigorous randomized controlled trial of RIV in pregnant women will provide much needed information on the overall safety for pregnant 
women and their infants , including adverse pregnancy outcomes, local and systemic 
reactogenicity, and vaccine- related adverse events .   Additionally,  assessing 
immunogenicity following maternal RIV  will add to the evidence base for maternal 
vaccination.  
 
2 STUDY OBJECTIVES  
Primary Objective:  
• PO1: To compare the proportions of adverse birth outcomes in pregnant women 
vaccinated with RIV4 ver sus IIV4.   
Research hypothesis:  The proportion of pregnant women with adverse birth 
outcome s will be noninferi or (not higher ) after receipt of  RIV4 compared to IIV4 
 
 
 
 
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
11 Secondary Objectives:  
• SO1: To compare proportions of preterm birth after RIV4 versus IIV4 vaccination  
• SO2: To compare proportions of combined fetal and neonatal death after RIV4 
versus IIV4 vaccination 
• SO3: To compare proportions of spontaneous abortion after RIV4 versus IIV4 
vaccination  
• SO4: To compare proportions of  moderate/severe soli cited reactogenicity events 
in pregnant women vaccinated with RIV4 versus IIV4  
 
Exploratory Objectives:  
• EO1: To compare and describe serious adverse events (SAE) in pregnant 
women vaccinated with RIV4 versus IIV4 
• EO2: To compare proportions of adverse pregnancy and birth outcomes of 
clinical interest after RIV4 versus IIV4 vaccination 
• EO3: To compare and describe health outcomes through 90 days  of life in infants 
born to women after RIV4 versus IIV4 vaccination 
• EO4: To compare maternal immune responses to influenza antigens after RIV4 
versus IIV4 vaccination  
• EO5: To compare cord blood antibody levels  for influenza antigens after RIV4 
versus IIV4 vaccination  
 
2.1 Study Outcome Measures 
2.1.1  Primary Outcome Measure:  
POM1: Proportions of adverse birth outcomes in pregnant women vaccinated  
with RIV4 versus IIV4   
Adverse birth outcome is a composite of occurrence of at least one of the 
following: preterm birth, spontaneous abortion, fetal death , or neonatal death.  
2.1.2  Secondary Outcome Measures:  
 
• SOM1: Proportions  of preterm birth after RIV4 versus IIV4  vaccination 
• SOM2: Proportions  of combined fetal and neonatal death after RIV4 versus IIV4 
vaccination  
• SOM3: Proportions of spontaneous abortion after RIV4 versus IIV4 vaccination 
• SOM 4: Proportions of pregnant women with moderate/severe solicited 
reactogenicity  event s (local and systemic)  within 8 days after vaccination with 
RIV4 versus IIV4  
 
2.1.3  Exploratory  Outcome Measures:  
 
• EOM1.1: Frequency and descriptions of serious adverse events  in pregnant 
women vaccinated with RIV4 versus IIV4  during the 42 days after vaccination  
• EOM1.2: Frequency and descriptions of serious adverse events in pregnant 
women vaccinated with RIV4 versus IIV4 during the study  
• EOM2.1. Proportions of infants born s mall- for-gestational age after RIV4 versus 
IIV4 vaccination.  
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
12 • EOM2 .2: Proportion of pregnant women with clinical chorioamnionitis after RIV4 
versus IIV4 vaccination 
• EOM2. 3: Proportion of women with preeclampsia or eclampsia after RIV4 versus 
IIV4 vaccination  
• EOM 3.1: Proportion of infants with medically -attended events through 90 days  of 
life after maternal RIV4 versus IIV4  vaccination  
• EOM 3.2: Frequency and description of SAEs in infants through 90 days of life 
after maternal RIV4 versus IIV4  vaccination.  
• EOM 3.3 Proportion of infants with neonatal death after maternal RIV4 versus 
IIV4 vaccination  
• EOM 4.1: Proportion of pregnant women achieving seroconversion at day 29 after 
RIV4 versus IIV4  vaccination [ a Hemagglutination Inhibition Assay ( HAI) titer > 
1:40 at day 29 if the baseline titer is < 1:10 or a minimum four-fold rise in HAI  titer 
if the ba seline  titer is > 1:10) for each influenza vaccine antigen] 
• EOM 4.2: Proportion of pregnant women with a seroprotective HAI titer (≥ 1:40) 
post-immunization at day 29 after RIV4 versus IIV4 vaccination for each  
influenza vaccine antigen 
• EOM 4.3: The maternal geometric mean HAI titer (GMT) pre and post -vaccination 
at day [ADDRESS_255523]/pre- vaccination ratio 
• EOM 5.1: Proportion of infants with cord blood seroprotective HAI titer (≥ 1:40) for 
each influenza vaccine antigen  after maternal RIV4 versus IIV4 vaccination  
• EOM 5.2: Infant cord blood geometric mean HAI titer (G MT) for each influenza 
vaccine antigen after maternal RIV4 versus IIV4 vaccination 
• EOM 5.3: Ratio of cord blood to maternal influenza antibody titers at time of 
delivery for each influenza vaccine antigen after maternal RIV4 versus IIV4 
vaccination  
 
3 STUDY DESIGN  
3.1 Main study design  
This study is a  prospective, randomized clinical trial  of approximately 430 pregnant 
women enrolled at Duke University Medical Center (Lead Contractor), Cincinnati 
Children’s Hospi[INVESTIGATOR_213029]  (Contributing Contractor) , and [LOCATION_011] Medical 
Center (Contributing Contractor) . Pregnant women ≥ 18 years of age at ≤ 34 weeks 
gestation, will be enrolled and randomized 1:1 to  receive either quadrivalent 
recombinant influenza vaccine (RIV4) or quadrivalent inactivated influenza vaccine 
(IIV4) . The designated vaccine brands for this study are Flublok® quadrivalent ([COMPANY_011]) 
and quadrivalent Flulaval® ([COMPANY_004])  (comparator IIV4) . However, the choice of IIV4 
vaccine administered will be based on availability from manufacturers prior to the 2019-[ADDRESS_255524] review from enrollment through 90 days  postpartum .  
3.2 Laboratory studies  
3.2.1  Serologic studies  – We will evaluate pre- and post -vaccination serologic 
responses in both IIV4 and RIV4 groups .  IgG levels will be measured for the 
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
13 specific viral  strains in cluded in the 2019- 2020  and 2020- 2021 quadrivalent 
influenza vaccines using hemagglutination inhibition assay s at the Duke  Regional 
Biocontainment Laboratory  (RBL) Virology Unit. Venous blood (approximately 15 
mL of blood) will be collected from each participant  before and 29 (-7 to +14) 
days after vaccination. At Duke, maternal and cord blood (approximately 15mL of 
blood each) collection will be performed at delivery for serological analysis in 
both RIV4 and IIV4 vaccination groups. At the other sites, these samples 
(maternal and cord blood) will be collected during delivery only  if feasible for 
similar serological analysis .  An assessment of placental antibody transfer 
(maternal:cord antibody ratio) will be determined.   
   
3.2.[ADDRESS_255525] yet to be identified that may be important 
for interpreting our study findings or of relevance to maternal -infant health 
outcomes.  Therefore, participants will be offered, through an opt -in/opt -out 
strategy to allow for the storage of any remaining blood (serum/plasma) after all 
specified analyses have been completed.  Additional laboratory assays may test 
for antibodies against other bacteria or viruses,  markers of inflammation, or used 
in research on the health of mothers and infants.  Specimens banked for use in 
other studies  will be linked to information  (including identifying information)  that 
participants provided to the study. Because it is unknown i f future testing will be 
of any utility, results of future testing will not be provided.  
In addition, participants will be offered, again through an opt -in/opt -out strategy, 
to allow study staff to contact [CONTACT_213043].    
 
4 STUDY ENROLLMENT AND WITHDRAWAL S 
4.1  Participant  Inclusion Criteria  
Participants  who meet  all of the following criteria will be eligible to participate in 
this interventional  study .   
1. Pregnant, as determined by [CONTACT_9870]  
2. Age ≥ 18 years of age  at enrollment  
3. Intention of receiving influenza vaccine based on ACIP -CDC guidelines  
4. Willing to provide written informed consent prior to initiation of any study procedures  
5. Gestational age at vaccination < [ADDRESS_255526]  
menstrual period and ultrasound dating. Estimated due date (EDD) and 
Gestational Age (GA -EDD) will be based on reconciliation of “sure” first day of 
the last menstrual period (LMP) and earliest dating ultrasound.   If the LMP is 
uncertain, then the  
 
 
 
 
Table 1. Ultrasound Parameters for Using Sure LMP to Determine 
Gestational Age  
Gestational age at first 
ultrasound by [CONTACT_213044]4 versus IIV4 in Pregnancy   Version 4.[ADDRESS_255527] dating ultrasound will be used to 
determine EDD and GA. If the ultrasound 
derived- EDD is in agreement with sure-
LMP derived EDD ( Table 1),  
then the LMP- derived EDD is used to 
determine GA. If the ultrasound derived 
EDD is not in agreement with the LMP -
derived EDD, the ultrasound- derived EDD is used to determine GA.  
6. English or Spanish literate 
7. Intention of being available for entire study period and complet e all relevant study 
procedures , including follow -up phone calls and collection of delivery information.   
 
4.2 Participant  Exclusion Criteria  
Participants who meet  any of  the following criteria will not be eligible to 
participate in this study:  
1. Influenza vaccine receipt during 2019 -2020 or 2020- 2021 influenza season prior 
to study enrollment.  
2. Participation in this study in 2019- 2020 influenza season 
3. Any condition that may interfere with assessment of local injection site reactions, 
e.g. obscuring tattoos  
4. Known or suspected immunosuppression as a result of an underlying illness or 
treatment  
5. Use of anti -cancer chemotherapy or radiation therapy within the preceding 36 
months  
6. Use of oral or parenteral corticosteroids  (≥ 20mg/day prednisone equivalent)  or 
high-dose inhaled glucocorticoid for ≥  14 consecutive days  within the preceding 
30 days   
7. Has an active neoplastic disease (excluding non -melanoma skin cancer), a 
history of any hematologic malignancy, current bleeding disorder, or taking 
anticoagulants (a daily aspi[INVESTIGATOR_89325])  
8. Has a history of receiving immunoglobulin or other blood product  (with exception 
of Rh  immunoglobulin) within the 3 months prior to study vaccination. 
9. History of febrile illness (> 100.4°F or 38°C) within the past 24 hours prior to 
study vaccination 
10. Contraindication to IIV or RIV receipt including history of severe allergic reaction 
after a previous dose of any influenza vaccine; or to a vaccine component, including egg protein   
11. History of Guillain -Barré  syndrom e within [ADDRESS_255528] -vaccination period  
13. Receipt of live vaccine during current pregnancy  
14. Signs or symptoms of active preterm labor, defined as regular uterine 
contractions with cervical change (dilation/effacement)  
15. Known multi -fetal gestation or fetal congenital anomaly, e.g. genetic abnormality 
or major congenital malformation based on antenatal ultrasound  
16. Anyone who is already enrolled or plans to enroll in another randomized clinical 
trial with any drug, vaccine or medical device. Co -enrollment in observational or 
behavioral intervention studies are allowed at any time  8 6/7 wk or less  ± 5 days 
9 0/7 wk to 13 6/7 wk  ± 7 days 
14 0/7 wk to 15 6/7 wk  ± 7 days 
16 0/7 wk to 21 6/7 wk  ± 10 days 
22 0/7 wk to 27 6/7 wk  ± 14 days  
28 0/7 wk and beyond  ± 21 days  
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
15 17. Any condition which, in the opi[INVESTIGATOR_7372], may pose a health risk 
to the participant or interfere with the evaluation of the  study objectives.   
18. Anyone who is a relative of any research study personnel  or is an employee 
supervised by [CONTACT_464]  
4.3 Recruitment  
Pregnant women at ≤ 34 weeks , ≥ 18 years old, who are planning to receiv e influenza 
vaccination during their current pregnancy  will be recruited at prenatal clinics  whose 
patients  deliver at Duke University Hospi[INVESTIGATOR_307]  (Duke) , University of Cincinnati Medical 
Center  (Cincinnati) , or [LOCATION_011] Medical Center  ([LOCATION_011]) . Pregnant women will be pre-
screened for eligibility via medi cal record review . The study will be introduced to a 
potential participant by a member of their care team. Potential participants that fall within 
the ≤ 34 weeks  gestation  range will be approached by a member of the research team 
for study enrollment. Medical and obstetric history, including prior influenza vaccine 
history , will be obtained via participant self -report with verification by [CONTACT_213045] (including medical records, employee health records, immunization 
registry records, and pharmacy records).  
4.4 Reasons for and Handling of Withdrawal s 
The following may be reason for study withdrawal:  
• As deemed necessary by [CONTACT_458] (PI) .  
• Participant  withdrawal of consent.  
• Loss to follow -up. 
• Termination of the study by [CONTACT_456].  
 Participants  may withdraw their consent for study participation at any time and for any 
reason, without penalty. Participants  who withdraw from the study prior to receiving 
study vaccine will be replaced. Participants  who withdraw from the study after receiving 
vaccine will not be replaced. Every attempt should be made to collect all data specified 
by [CONTACT_760], including collection of pregnancy outcome/safety data via medical record 
review for participants who request withdrawal from study interventions/procedures .  
 
4.5 Termination of Study  
This study may be terminated for safety concerns of the principal investigator s from the 
Lead or Contributing sites, CDC, or participating IRBs.    
 
5 STUDY SCHEDULE, PROC EDURES, & EVALUATIONS 
5.1 Schedule of events  
Pregnant women meeting the proposed eligibility criteria will be recruited. Written 
informed consent  (will be obtained from study participants prior to conducting any study 
procedures. Table  [ADDRESS_255529] blood and maternal blood collection at Visit 6 will be optional  and collected when feasible by [CONTACT_779].  
 
Screening Visit, Study Day - 30 to 1 (Chart Abstraction & Clinic Visit  – may occur 
simultaneously with Visit 1)  
• Obtain written  informed consent and release of medical record information 
• Review  and confirm study eligibility  
• Obtain information on preferred method of contact [CONTACT_20687] -up (telephone or email 
reminder  or text reminder ) 
• Obtain demographic  data  
• Obtain influenza vaccination history  
• Obtain m edical  history  (e.g. chronic hypertension, diabetes, autoimmune disorder),  
obstetric history ( e.g. parity, prior preterm birth, low birthweight , small for gestational 
age), and current pregnancy status ( e.g. gestational diabetes, gestational 
hypertension, placenta previa, estimated due date)  
• Obtain concomitant medication use  
  
 Table 1. Study Visit Schedule  
Procedure  Screening 
Visit*  
Day -30 to 1  Visit 1  
Day 1  Visit 2  
Day 4 + 1 Visit 3  
Day 9 + 3  Visit 4  
Day  29        
-7/+14   Visit 5  
Day 43 + 7  Visit 6  
Delivery  Visit 7  
Postnatal 
Day 90 + [ADDRESS_255530]  Chart 
Abstraction/ 
Clinic  Clinic  Phone/Text/
Email/ Data 
Review Phone/Text
/Email/ Data 
Review Clinic  Phone/ Text/
Email/ Chart 
Abstraction  Hospi[INVESTIGATOR_307]/ 
Chart 
Abstraction  Phone/ Text/
Email/ Chart 
Abstraction  Clinic  
Informed consent & Medical 
Release of Information  X         
Review Eligibility Criteria  X X        
Demographic, Medical, and 
obstetric  history  X X        
Influenza Vaccination History  X X        
Vital signs ( temperature, blood 
pressure,  and heart rate)   X       X 
Blood Sample Collection   X   X  X1   
Randomization  and 
Vaccination   X        
Obtain immediate adverse 
event information   X        
Dispense memory aid   X        
Dispense study supplies   X        
Complete Memory aid form 
(REDCap or paper)   X X X      
Concomitant 
medications/vaccinations  X X X X X X X X X 
Obtain solicited adverse 
events  X X X      
Obtain unsolicited adverse 
events  X X X     X 
Obtain serious adverse event 
information   X X X X X X X X 
Infant data collection         X  
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
17 Visit 1, Study Day 1 - Screening,  Enrollm ent, and Vaccination (Clinic  Visit)  
• If Screening Visit occurred prior to Visit 1, review and confirm eligibility and all data 
collected during Screening Visit  
• Obtain vital signs including oral tem perature  prior to vaccination 
• Obtain 15mL (~2 tubes)  blood sample prior to vaccination for serologic analysis  
• Randomize study participant to RIV4 or IIV4  
• Administer  assigned study product – t rained, licensed staff will serve as unblinded 
vaccinators to administer either RIV4 or IIV4 as described in Section A.4.3.  Participants 
and a ll other study personnel  involved in collection of memory aids, follow -up phone 
calls, data collection, etc. will be blinded to randomization arm.  
• Ensur e participants receive the CDC Influenza Vaccine Information Statement  
(VIS)  dur ing  the visit. 
• Observe participants for  at least [ADDRESS_255531] any 
immediate adverse events (AEs)  
• Dispense oral thermom eter, ruler (in order to standardize measurements)  and 
memory aid . Review instructions for use of thermometer, ruler, and  mem ory aid 
completion.    
• Participants will be given the choice of completing the memory aid electronically or on paper.  Participants who select the electronic method will enter their data into a 
REDCap web-based system  
• Confirm preferred method of contact [CONTACT_20687] -up (telephone, email , or text 
reminder)  
• Confirm date of study Visit 4 (attempt to coincide with regularly scheduled prenatal 
visit as feasible) 
• Review concomitant medication use  
• Study staff will instruct  participants to  
• Notify the study staff if they are hospi[INVESTIGATOR_213030] a severe adverse event 
• Follow up with their healthcare provider if they have any symptoms they find concerning 
• Notify study staff if they enroll in another research study  
 Visit 2, Study Day 4 (window Days 3 – 5 ) Phone/Text/Email/Online Memory Aid 
review  
• Participants  will complete their memory aid via paper or electronic entry  from 
Day 1 -8. 
• Participants using paper diary:  
o Study staff will contact [CONTACT_213046] (solicited and unsolicited), 
serious AEs (SAEs), pregnancy status, and concomitant medications.   
o Participants will be  
 Asked to n otify the study staff if they are hospi[INVESTIGATOR_213030] a 
severe adverse event,  
 Follow up with their healthcare if they have symptoms they find 
concerning 
 Reminded that they will be contact[CONTACT_213047] 9 and Day 12 for Visit 3  
 
• Participants using REDCap web- based system : 
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.[ADDRESS_255532] participants if more 
information is needed to better describe AEs [including SAEs and severe 
(Grade 3)  event s] reported in the REDCap web-based system . 
o All participants using REDCAP web -based will be   
 Reminded to continue data entry into REDCap web-based system  
 Asked to n otify the study staff if they are hospi[INVESTIGATOR_213030] a 
severe adverse event,  
 Follow up with their healthcare provider if they have symptoms they 
find concerning 
 
Visit 3, Study Day 9 (window Days 9 –  12) Phone/Text/Email/Online Memory Aid 
Review  
• Participants  will complete their memory aid via paper or electronic entry  from 
Day 1 -8.  
• Participants using paper diary:  
o Study staff will contact [CONTACT_213048]  (solicited and unsolicited) , 
serious AEs (SAEs), and concomitant medications.  
o Remind participants to  
 Notify the study staff if they are hospi[INVESTIGATOR_213030] a severe 
adverse event,  
Follow up with their healthcare if they have symptoms they find 
concerning 
o Confirm date of next scheduled study visit (attempt to coincide with 
regularly scheduled prenatal visit as feasible)  
 
• Participants using REDCap web-based system : 
o Study staff will review REDCap system to confirm data capture and 
assess for any AEs, SAEs, and concomitant medications.   
o The study team will contact [CONTACT_213049]. The study team may also contact [CONTACT_213050] [including SAEs and severe 
(Grade 3)  event s] reported in the REDCap web-based system . 
o All participants using REDCAP web -based will be   
Asked to n otify the study staff if they are hospi[INVESTIGATOR_213030] a 
severe adverse event,  
 Follow up with their healthcare if they have symptoms they find 
concerning 
 Have their date for next scheduled study visit confirmed ( attempt to 
coincide with regularly scheduled prenatal visit as feasible) . 
   
Visit 4, Study Day 29 (window Days 21  – 42) Clinic Visit  
• Study staff will review the memory aid data (paper or electronic)  and record any SAEs  
and concomitant medications  
• Obtain 15mL  (~2 tubes)  blood sample for serologic analysis  
• Confirm preferred method of contact [CONTACT_20687] -up (telephone, email , or text 
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
19 reminder)  
•  Remind participants   
o They will be contact[CONTACT_213051] 43 – [ADDRESS_255533] symptoms they find 
concerning 
 
Visit 5, Study Day 43 (window Days 43 - 50) Phone Call /Text/Email  Follow -Up/Chart 
Abstraction  
Study staff will contact [CONTACT_213052].  Medical records will be reviewed to obtain more information about any 
SAEs . Participants will be reminded that they may be contact[CONTACT_213053] ~ [ADDRESS_255534] Review/Phone Call/  Hospi[INVESTIGATOR_213031] a 
daily basis to identify study participants admitted for delivery. Medical records will 
be reviewed for maternal and infant outcomes  as well as maternal Tdap receipt.  At 
Duke, maternal and cord blood collection will be performed at delivery. At the other 
sites, these samples (maternal and cord blood) will be col lected during delivery if 
feasible. Study participants who are not identified via review  of inpatient census 
records will be contact[CONTACT_41576] 2 weeks after their estimated due date to 
determine if delivery occurred elsewhere. If so, maternal and inf ant medical records 
will be requested from the delivery hospi[INVESTIGATOR_213032].   
For the pregnancy outcomes abortion (spontaneous or elective termination) or fetal 
death, medical records will also be reviewed. Study participants with these 
outcomes w ill be contact[CONTACT_213054].   
 Visit 7, Postnatal Day 90 (window Postnatal Days 90 - 104) Phone Call /Text/Email  
Follow -Up/Chart Abstraction  
Study staff will contact [CONTACT_213055], including 
neonatal/infant death and re- hospi[INVESTIGATOR_059], and concomitant medications . Information will 
also be collected on emergency room  visits and unanticipated visits to the primary care 
pediatrician or a specialis t. Data will be verified via review of medical records
.  Sites will 
have subjects sign medical records release forms for both themselves and their infants  
at the time of inform ed consent .   This is done so that in the event subjects and/or their 
infants are seen outside of the site’s medical coverages, that medical records regarding their emergency room or unanticipated visits can be requested.   
For neonatal deaths identified by [CONTACT_213056] 7, study participants will contact [CONTACT_213057].  
 
*Unscheduled Visits  
• Obtain vital signs including oral temperature for the pregnant women  
• Record any solicited and unsolicited AEs through Day  8, maternal and infant 
SAEs  and concomitant medications  through 90 days  after delivery  
• Confirm preferred method of contact [CONTACT_20687] -up (telephone, email, or text 
reminder )  
 
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.[ADDRESS_255535] subjects  with an IRB -
approved letter  by [CONTACT_213058], email or patient portal message (e. g., MyChart)  to inform 
them which vaccine they received.  
.  
Treatment Assignment Procedures  
This is a randomized, controlled, double -blinded study involving pregnant women who 
are to receive the influenza vaccine.  The designated vaccine brands for this study are 
Flublok ® quadrivalent ([COMPANY_011]) and quadrivalent Flulaval ® ([COMPANY_004])  (IIV4) . However, the 
specific comparator IIV4 vaccine administered will be  based on availability from 
manufacturers prior to the 2019- 2020  and 2020 -2021 influenza seasons. To the extent  
feasible, the same influenza vaccine brand will be used as the comparator vaccine during both influenza seasons at all recruiting  sites.  
 
5.1.1  Randomization  
Participants will be randomized (1:1) to receive either RIV4 (Flublok® quadrivalent 
recombinant influenza vaccine) or IIV4 (quadrivalent inactivated influenza vaccine) using 
a permuted block randomization scheme stratified by [CONTACT_3885]  (Duke, Cincinnati, 
[LOCATION_011]) . The project statistician will generate permuted  block randomization schemes 
which will be uploaded to REDCap (section 7.2.1) . The randomization schedule will not 
be available to the study staff, so the next randomization allocation will not be known 
before randomization occurs. Following confirmation o f study eligibility criteria during 
Visit 1, participant randomization will be through REDCap with treatment allocation 
recorded on the case report form ( CRF).  
In the event that REDCap is unavailable, manual randomization will occur through the use of env elopes. The project statistician will prepare 20 envelopes per  gestational  age 
group per site (total of 40 per site) that will use the same randomization strategy as the 
primary scheme embedded in REDCap. When an unblinded team member is informed 
of the  gestational  age group, he/she will pull the next envelope in order. In order to 
capture the allocation per subject, a separate form in REDCap will be used by [CONTACT_188947]. A log will need to be kept at the site 
capturing thes e instances.  
 
5.1.2  Blinding  
This study is double- blinded, therefore study  staff and participants  will be blinded to 
randomization assignments .  Trained, licensed staff will serve as unblinded vaccinators 
to administer either RIV4 or IIV4.  All other study personnel  involved in collection of memory 
aids, follow -up phone calls,  and data collection, will be blinded to randomization arm.  
Laboratory staff will be blinded to randomization arm assignment .   
 
The participant will receive documentation of receipt of influenza vaccine without 
specification of whether it was RIV4 or IIV4 vaccine to preserve blinding.  In the event of 
individual participant clinical safety issues or overall study safety concerns, t hen blinding 
may be broken.  
 
5.1.3  Vaccine Supply, Storage, and Administration  
In order to ensure adherence to study randomization assignment, licensed RIV4 and 
IIV4 vaccines will be administered as study procedures. Licensed RIV4 and IIV4 will be 
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
21 purchased for study administration and will be stored  at 2° to 8°C in a research- specific 
medication refrigerator. While research staff maintain daily temperature logs for the 
medication refrigeration, it is also monitored 24/[ADDRESS_255536] 
to report to the research center for further investigation. Flublok® quadrivalent ([COMPANY_011]) 
and quadrivalent Flulaval® ([COMPANY_004]) will be the designated study products .  
A single  admi nistration  of both RIV4 and IIV4 comp rises  intramuscular  delive ry of 0.5mL  
total volume of each vaccine for adults.  Unblinded, licensed provider s will prepare the 
RIV4 or IIV4 by [CONTACT_213059]. 
Vaccine lot numbers will be recorded in the study accountability log available only to 
unblinded licensed staff or the investigational pharmacist. Dose and site of vaccine 
administration will be recorded by [CONTACT_213060]. RIV4 and IIV4 will be 
administered in the deltoid of the patient’s preferred arm by [CONTACT_213061] . After administration, used study syringes will be disposed of according to 
standard operating procedure.  
 
A licensed provider who will be trained on the study protocol, will be present at the time 
of vaccine administration  along with emergency management supplies available for 
initial treatment of an allergic reaction if needed. Additionally, a blinded post -assessment 
team will be present to assist study participants  following vaccine administration; they 
will not be in the room at the time of vaccination.  
5.[ADDRESS_255537] -vaccination and queried for any 
adverse events immediately following vaccination (e.g. wheezing, rash, dizziness, fainting) and recorded.  
Frequency and occurrence of local and systemic reactogenicity, unsolicited adverse events (AEs), serious AEs (SAEs), concomitant medication use, and unscheduled medical care will be assessed through post -vaccination Day [ADDRESS_255538] -vaccination 
symptoms. Beginning on the evening of Study Visit 1 (Day 1 ) following influenza 
vaccination, participants will record their oral temperature using the study -supplied 
thermometer for the next 8 days (Day 1 – 8 ). Temperature will be recorded at roughly 
the same time each day  or when a participant feels feverish. If a temperature ≥ 100.4 °F 
(38°C) is recorded, a second measurement will be taken. If more than one temperature 
is taken on the same day, the highest temperature should be recorded. Fever will  be 
defined as a measured temperature ≥  100.4°F (38°C).  Participants will classify local a nd 
other systemic reactogenicity events as mild, m oderate, or severe as described in Table 
4 and 5 . 
During Visits 2 , 3, and 4 information reported by [CONTACT_213062]. Participants who report severe solicited advers e events or 
express any concern about symptoms/unsolicited events will be encouraged to follow up with their obstetrician or primary care provider. Study staff will assist with coordination of 
referral appointments as necessary. Medical records will be obtained and reviewed for 
any unscheduled medical appointment  through post -vaccination Day 43.  
Table 4: Injection -site Reactogenicity*  
Symptom  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
22  
Table 5: System Reactogenicity*  
Systemic  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Fever **  ≥100 .4 to ≤101.1° F  ≥101.2 to ≤102.0° F  ≥102. 1° F 
Malaise (Fatigue) Noticeable but does not 
interfere with activity  Interferes with activity but did not 
necessitate medical visit or absenteeism  Prevents daily activity and resulted in medical visit or absenteeism  
Myalgia (Body 
aches)  Noticeable but does not 
interfere with activity  Interferes with activity but did not necessitate medical visit or absenteeism  Prevents daily activity and resulted in medical visit or absenteeism  
Arthralgia  (Joint 
pain)  Noticeable but does not interfere with activity  Interferes with activity but did not necessitate medical visit or absenteeism  Prevents daily activity and resulted in medical visit or absenteeism  
Nausea  Noticeable but does not 
interfere with activity  Interferes with activity but did not 
necessitate medical visit or absenteeism  Prevents daily activity and resulted 
in medical visit or absenteeism  
Vomiting Noticeable but does not interfere with activity  Interferes with activity but did not 
necessitate medical visit or absenteeism  Prevents daily activity and resulted 
in medical visit or absenteeism  
Diarrhea  Noticeable but does not interfere with activity  Interferes with activity but did not 
necessitate medical visit or absenteeism  Prevents daily activity and resulted 
in medical visit or absenteeism  
Abdominal pain  Noticeable but does not interfere with activity  Interferes with activity but did not 
necessitate medical visit or absenteeism  Prevents daily activity and resulted in medical visit or absenteeism  
Headache  Noticeable but does not 
interfere with activity  Interferes with activity but did not 
necessitate medical visit or absenteeism  Prevents daily activity and resulted in medical v isit or absenteeism  
Chills/shivering  Noticeable but does not 
interfere with activity  Interferes with activity but did not 
necessitate medical visit or absenteeism  Prevents daily activity and resulted in medical visit or absenteeism  
** Oral temperature, no recent hot/cold beverages or smoking  
 
Administration  of influenza vaccines including IIV and RIV  is routine clinical care during 
pregnancy such that we do not anticipate having a significant issue with serious adverse 
events (SAEs). However, we will monitor study participants  and their infants  for SAEs 
during the protocol -defined surveillance period [i.e. from enrollment  through 90 days 
postpartum] .  
An SAE is defined as an AE that meets one of the following conditions: 
• Results  in death  (including SAB and fetal death) during  the period of protocol -
defined surve illance   
• Is life -threatening (defined as im mediate risk of death  at the time of the  event)  
• Requires  inpatient  hospi[INVESTIGATOR_213033] -defined surveillance (other than routine hospi[INVESTIGATOR_213034] 
& delivery)  
• Results  in congenital  anom aly or birth defect  
• Results  in a persi stent or significant disability/in capacity  
• Any other  important  medical  event  that may not result  in death,  be life threatening,  or Pain  Noticeable but does not 
interfere with activity  Interferes with activity  but did not 
necessitate medical visit or absenteeism   Prevents daily activity  and resulted in 
medical visit or absenteeism  
Tenderness  Noticeable but does not 
interfere with activity  Interferes with activity but did not 
necessitate medical visit or absenteeism    Prevents daily activity and resulted in 
medical visit or absenteeism  
Induration/  
Swelling  25 to ≤ 50 mm   51 to ≤ 100 mm   >100 mm   
Erythema  25 to ≤50 mm  51 to ≤100 mm  >100 mm 
*Injection -site criteria being used in the CISA Study on Safety of  RIV4 versus IIV4   in Pregnant Women  
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.[ADDRESS_255539]. If deemed necessary, we will designate an 
independent safety monitor with relevant expertise, in collaboration with the CDC.
 
 If indicated, adverse events (AEs) will be reported to the CDC’s Vaccine Adverse Event 
Reporting System (VAERS). The National Childhood Vaccine Injury Act requires 
healthcare providers to report:  
• Any adverse event listed by [CONTACT_29386] a contraindication to 
further doses of the vaccine; or  
• Any adverse event listed in VAERS Table of Reportable Events following 
Vaccination (accessed at 
https://vaers.hhs.gov/docs/VAERS_Table_of_Reportable_Events_Following_Vaccinati
on.pdf  )  t hat occurs within the specified time period after vaccination.  
 
In addition, CDC encourages reporting of any clinically significant adverse event that 
occurs in a patient . 
 Study site investigators will assess relatedness to vaccine or study procedures (related, 
possibly related, unlikely related, or not related) for all AEs including SAEs. The study 
investigators will use their clinical judgement to make causality assessments and the final causality assessment decision is the responsibility of the site principal investigator 
[INVESTIGATOR_188927].  
 
5.3 Biospecimens Collection & Handling  
5.3.[ADDRESS_255540] operating procedures and not contain personal identifiers.   Serum aliquots will 
be frozen and stored  at each site  until planned laboratory analyses.  
The Study site(s) will process and ship these samples to Duke using standard 
procedures, in accordance with specimen transport policies . 
Any unused serum samples will be returned to the study site(s) after all assays have 
been completed.   
 
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
24 6 LABORATORY ANALYSES  
6.1 Influenza Laboratory Analysis  
Flublok® quadrivalent ([COMPANY_011]) and quadrivalent Flulaval®  ([COMPANY_004]) will be the designated 
study products . An alternate licensed IIV4  may be used in place of Flulaval® i f there are 
unforeseen issues.  
As such, reference wild- type, reassortant, or vaccine virus strains representative of the 
specific viral antigens included in the 2019- 2020 or 2020 -2021 influenza vaccines will be 
used to evaluate the relative levels of all four influenza strain -specific antibodies in 
maternal serum ( pre- and post -vaccination) and infant cord blood.  To accomplish these 
activities all patient samples  will be interrogated for influenza antibodies against the 
strains of interest using the influenza hemagglutination inhibition assay (H AI).  This 
assay is considered the “gold- standard” measure by [CONTACT_188950]/seroprotection in response to seasonal influenza vaccination. This assay 
will be performed in accordance with the Duke RBL Virology Unit’s fully optimized and 
approved SOP (RVUSOP004 Influenza HI of Serum Samples).  Briefly, test samples will 
be assayed by [CONTACT_213063] 2- fold dilution series starting at 1:10.  Serum dilutions 
are then incubated with a concentration of virus verified to possess a known potential for red blood cell (RBC) agglutination.  The presence of virus -specific antibodies is 
visualized via incubation of the virus -serum mixture with a RBC solution; the endpoint 
titer for a given dilution series is then expressed as the reciprocal of the final dilution in which complete H AI is observed.  By [CONTACT_559], seronegative samples are defined as 
having an endpoint H AI titer < 1:40 and seropositive samples as having an endpoint titer 
of ≥ 1:40; and seroconversion as a HAI titer ≥ 1:40 at day 29 if the baseline titer is < 1:10 
or a minimum four-fold rise in HAI  titer if the baseline titer is ≥ 1:10 for each influenza 
vaccine antigen.  
 
7 STATISTICAL CONSIDER ATIONS  
In collaboration with the [LOCATION_011] Medical Center , Cincinnati Children’s Hospi[INVESTIGATOR_7725] , and CDC the research team at Duke will oversee the statistical analysis. Data 
will reside on a secure Duke server m aintained by [CONTACT_213064] 
(DHTS).  For the study, a database will be developed and a data set for the study 
without personal identifiers will be made available to the CDC upon request.  Duke 
statisticians will develop a comprehensive St atistical Analysis Plan.  The summary points 
of the analysis plan are presented below.  
7.1 Definitions  
Pregnancy and birth outcomes in this study will be defined by [CONTACT_213065]’s REVITALIZE Obstetric Data Definitions
16, CDC 
national Vital  Statistic System17 or  World Health Organization18 if available.   
Definitions for the component of the primary outcome measures are as follows:  
• Preterm birth - born alive at  less than 37 weeks and 0 days  gestation  
• Spontaneous abortion (SAB) - pregnancy loss prior to 20 weeks 0 days  
• Fetal death - intrauterine death of fetus at or after 20 weeks 0 days  
• Neonatal death - infant death within first 28 days of life  
7.2 Sample Size and Power Estimation  
Allowing for a 5% drop out rate and given an initial N=430, there should be 
approximately 408 participants for evaluation. We assume that 15% of pregnant 
women will have adverse birth outcomes after vaccination with RIV4 or IIV4, based 
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.[ADDRESS_255541] selected a 
clinically meaningful noninferiority margin of 10%.  Statistical calculations show that 
with a one -sided alpha of 0.[ADDRESS_255542] 80% power to reject the null hypothesis that RIV4 is noninferior to IIV4 in the  proportion of adverse birth outcomes.  
 
7.3 Analysis Plan  
7.3.1  Study Populations  – There will be three  study populations t he modified Intent -to-
treat (mITT), Per Proocol (PP), and Immunogenicity  populations.  The m ITT Population 
includes any participant that was enrolled, randomized into the study, and received 
vaccine. The PP Population is a subset of the ITT Population excluding those 
participants with major protocol violations . The Immunogenicity Population is a subset of 
the mITT Population that includes only subjects who received vaccine, provide baseline 
and Visit 4 blood draws available for analysis within the protocol- defined time frame, and 
with no protocol violations affecting immunogenicity.  These protocol violations will be 
listed in the Statistical Analysis Plan.  Statistical analyses  of the safety outcomes  will be 
performed for both mITT and PP populations, and immunogenic outcomes will be 
analyzed for the Immunogenicity Population.  
 
7.3.2    Alpha Level  - No adjustment to the alpha level will be made for the secondary and 
exploratory objectives.  
 
7.3.3   Primary Objective - To compare the proportions of adverse birth outcomes in 
pregnant women vaccinated with RIV4 versus IIV4.      
o Research hypothesis: The proportion of pregnant women with adverse birth 
outcomes will be non- inferior (not higher  – based on the noninferiority margin) 
after receipt of RIV4 compared to IIV4 . 
This objective will be assessed using a one- sided noninferiority test with the 
alpha level set at 0.025  (1-sided)  and a noninferiority margin of 10%.   
The null hypothesis assumes that  RIV4  is inferior to IIV4  in regards to the 
proportion of pregnant women with adverse birth outcomes . 
    Ho: RIV4  - IIV4 ≥ 0.10 (10%) 
 The alternative hypothesis states that  RIV4  is noninferior to IIV4  in regards to 
the proportion of pregnant women with adverse birth outcomes . 
   Ha: RIV4  - IIV4 < 0.10 (10%) 
 The upper bound of a stratified (by [CONTACT_3885])  Newcombe binomial confidence 
interval (Yan and Su 2010) with Cochran- Mantel -Haenszel (CMH) weighting of 
the difference will be used to make this assessment.  
 
A composite outcome for adverse birth outcome [ defined by [CONTACT_213066]: preterm birth, spontaneous abortion, fetal 
death or neonatal death]  will be used as the primary study endpoint.    
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.[ADDRESS_255543] Mantel -Haenszel statistic (calculated in 
Proc Logistic in SAS) in a stratified analysis by [CONTACT_213067]- sided alpha 0.05 level.  The site adjusted relative 
risk and corresponding 95% confidence interval for the proportion of preterm birth 
will also be calculated.    
7.3.[ADDRESS_255544] Mantel -
Haenszel statistic (calculated in Proc Logistic in SAS) in a stratified analysis by 
[CONTACT_174907]- sided alpha 0.05 level.  The 
site adjusted relative risk and corresponding 95% confidence interval for the proportions of combined fetal death and neonatal death will also be calculated.  
 
7.3.[ADDRESS_255545] Mantel -Haenszel statistic 
(calculated in Proc Logistic in SAS) in a stratified analysis by [CONTACT_213068]- sided alpha 0.05 level.  The site adjusted 
relative risk and corresponding 95% confidence interval for the proportion of spontaneous abortion after vaccination will also be calculated. This will be a 
subgroup analysis of only those participants vaccinated at less than 20 weeks 
gestational age.  
 
7.3.7     Secondary Objective 4 - To compare proportions of moderate/severe solicited 
reactogenicity events in pregnant women vaccinated with RIV4 versus IIV4. 
Reactogenicity will be assessed for 8 days following the vaccination at Visit 1. These proportions will be presented by [CONTACT_1570], symptom, and grade 
level (moderate/severe) for women with injection site reactogenicity within [ADDRESS_255546] Mantel -Haenszel statistic 
(calculated in Proc Logistic in SAS) in a stratified analysis by [CONTACT_174907]- sided alpha 0.[ADDRESS_255547] ogenicity will be presented in a similar fashion.  
 
7.3.8  E
xploratory Objective 1: To compare and describe serious adverse events (SAE) 
in pregnant women vaccinated with RIV4 and IIV4 . The proportion and 95% 
exact binomial confidence interval of serious adverse events (SAEs) , as well as 
the total number of events, will be presented by [CONTACT_3725], vaccine group, severity, and relatedness.  Listings of these SAEs  will also be presented.  Non- overlappi[INVESTIGATOR_213035] a statistical difference between the groups.  These presentations and listings will be provided for the participant’s 
study duration  and for the first 42 days after vaccination.  
 
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
27 7.3.9      Exploratory Objecti ve 2: To compare proportions of adverse birth outcomes of 
clinical interest after RIV4 versus IIV4 vaccination. These proportions (i.e., 
infants born small -for-gestational age, pregnant women with clinical 
chorioamnionitis, and pregnant women with preeclampsia or eclampsia) will be 
compared between the RIV4 group and the IIV4 group using an exact Mantel -
Haenszel statistic (calculated in Proc Logistic in SAS) in a stratified analysis by 
[CONTACT_174907]- sided alpha 0.05  level.   
 
 
7.3.10  Exploratory Objective 3: To compare and describe health outcomes through [ADDRESS_255548] Mantel -Haenszel statistic (calculated in 
Proc Logistic in SAS) in a stratified analysis by [CONTACT_213067]- sided alpha 0.05 level. The proportion and 95% 
exact binomial confidence interval of SAEs in infants through 90 days of life, as well as the total number of events, will be presented by [CONTACT_3725], vaccine group, severity, and relatedness.  Listings of these SAEs will also be presented.  Non-
overlappi[INVESTIGATOR_213036] a statistical difference 
between the groups . 
 
7.3.11  Exploratory Objective 4: To compare maternal immune responses to influenza 
antigens and calculate the post and pr e-vaccination ratio after RIV4 versus IIV4 
vaccination. The proportion of pregnant women achieving seroconversion at day 
29 and the proportion pregnant women with a seroprotective HAI titer ( ≥ 1:40) 
pre- and post -immunization at day 29 will be compared using a Mantel -Haenszel 
statistic in a stratified analysis by [CONTACT_174907]- sided alpha 0.05 level. The geometric mean HAI titer (GMT) pre - and 
post-immun ization at day 29 after RIV4 versus IIV4 vaccination for each 
influenza vaccine antigen will be compared (within vaccine arm pre versus post 
and within timeframe RIV4 versus IIV4) using a regression model with the log 
transformed titer value at the two- sided alpha 0.05 level.  
 
7.3.12  Exploratory Objective 5: To compare cord blood antibody levels for influenza 
antigens after RIV4 versus IIV4 vaccination. The proportion of infants with cord 
blood seroprotective HAI titer will be compared using a Mantel -Haenszel statistic 
in a stratified analysis by [CONTACT_174907]-sided alpha 0.[ADDRESS_255549] blood geometric mean HAI titer (GMT) for 
each influenza vaccine antigen will be compared using a regression model with 
the log  transformed titer value at the two- sided alpha 0.05 level. The ratio and 
95% confidence interval for cord blood to maternal influenza antibody titers at time of delivery for each influenza vaccine antigen after maternal RIV4 versus IIV4 vaccination will be presented. Non -overlappi[INVESTIGATOR_213037] a statistical difference between the groups.  
 
7.3.[ADDRESS_255550] treatment (i.e., treatment other than what they were randomized to receive), then the primary and 
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.[ADDRESS_255551] 
for this study.  However, because RIV4 safety in pregnancy has not been 
systematically studied, an interim safety data review of all serious adverse events (SAEs) will be performed with the goal of identifying unexpected safety concerns 
of clinical importance. The safety data review will provide the study the 
opportunity to ma ke changes to the protocol, if needed, prior to enrollment in the 
2020- [ADDRESS_255552] step. This is to avoid introducing bias or increasing sample size needs for 
statistical power.  
 
7.3.16  Further analysis 
Prior to the second season of enrollment, randomization was stratified by 
[CONTACT_58032] (<20 weeks versus 20 -34 weeks) and by [CONTACT_3725].  Stratification by 
[CONTACT_213069] 2.[ADDRESS_255553]  will be substantial and 
will require a sophisticated, practical and flexible system that can accommodate different modes of data collection and several separate linked surveys. The novel Vanderbilt -
designed resource developed specifically for online collection of research information, 
the Research Electronic Data Capture (REDCap) platform, will be used to design study 
forms, including the reaction forms, and short customized questionnaires to collect information from study participants . This system will be used by [CONTACT_188951].  All electronic linkages will fulfill regulations for protection of human 
participants  and requirements to minimize the risk of breach of confidentiality. After initial 
set-up, the work load required for electronic data collection will be substantially reduced 
(description of REDCap resources below). Duke investigators have previously used the 
REDCap system for collection and analysis of large quantities of data.  Participants will 
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
29 be given the option to fill out their memory aid  either directly i n the REDCap system or 
on paper. All study -related documents containing protected health information, e.g. 
enrollment logs, case report forms, memory aids completed by [CONTACT_19288], will be 
maintained in secure research offices at Duke, which are accessible to research staff 
only.  
 
7.4.1 Research Electronic Data Capture (REDCap)  
Investigators within the NIH -funded Clinical and Translational Research Unit at 
Vanderbilt have developed REDCap ( http://project -redcap.org/ ), to collect and manage 
data for diverse clinical and translational research studies. REDCap was designed 
around the concept of giving research teams an easy method to specify project need s 
and rapi[INVESTIGATOR_174848], web- based applications for collection, management and 
sharing of research data. REDCap accomplishes these key functions through use of a single study metadata table referenced by [INVESTIGATOR_44605]- level operational modules. 
Based on this abstracted programming model, databases are developed in an efficient manner with little resource investment beyond the creation of a single data dictionary. 
The concept of metadata -driven application development is well established, and the 
critica l factor for successful data collection lies in creating a simple workflow 
methodology allowing research teams to autonomously develop study -related metadata 
in an efficient manner.
[ADDRESS_255554] with Duke University, Cincinnati Children’s 
Hospi[INVESTIGATOR_213038].  CDC staff will collaborate with the sites to develop the protocol, conduct the study, ensure the study is aligned with US Department of Health and Human Services 
(CDC) public health priorities, and analyze the data and disseminate the results. CDC 
may receive access to coded data not containing any directly identifying information.  
 
[ADDRESS_255555] a waiver of consent  
and HIPAA authorization for ascertainment (identification, selection) and/or recruitment 
of potential participants  while recording identifiable private health information (PHI)  prior 
to obtaining the participant’s  consent.  This information will be obtained fr om review of 
the electronic scheduling and medical record systems in the clinics  in order to determine 
eligibility for study enrollment. We will review information only the minimum amount of 
information necessary to determine eligibility, i.e. date of birt h, current pregnancy status, 
pregnancy history, medical and surgical history, ultrasounds pertaining to current pregnancy, and recent laboratory test results. The PHI collected prior to consent will be 
used to recruit and screen only. Use of PHI in this ma nner involves no more than 
minimal risk to participants and no information will leave the study sites . 
 
Continuing reviews will be submitted to the IRBs  in accordance with the new Common 
Rule.
[ADDRESS_255556] solicited adverse reactogeni city events and 
any medical intervention sought on the day of and 7 days following vaccinations  on the 
memory aid . Memory aid information will be reported to the study team during a 
telephone call or in the web- based REDC ap system. The research staff will assess one 
or more of the following:  weight, height, temperature, blood pressure, and pulse.   
8.[ADDRESS_255557] clinical practice and recommended by [CONTACT_213070].   Participants wil l be provided with 
the CDC Vaccine Information Statement (VIS) for IIV  and RIV .  
 
IIV and RIV  risks include minor problems  such as soreness, redness, swelling , or pain  
where the shot was given, hoarseness , sore, red or itchy eyes , cough , fever , aches , 
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
31 headache, itching , fatigue , all of which usually occur within 1- 2 days of vaccination and 
are self -limiting. Syncope (fainting) can occur in association with administration of 
injectable vaccines . More serious problems  including a small increased risk of Guillain -
Barré Syndrome estimated at 1 or 2 additional cases per million people vaccinated. This 
is much lower than the risk of severe complications from in fluenza infection, which can 
be prevented by [CONTACT_213071] .  (http://www.cdc.gov/vaccines/hcp/vis/vis -
statements/flu.html ). 
 
Problems that could happen after any injected vaccine:  
• People sometimes faint after a medical procedure, including vaccination. Sitting 
or lying down for about [ADDRESS_255558] 
vision changes or ringing in the ears.  
• Some people get severe pain in the shoulder and have difficulty moving the arm 
where a shot was given. This happens very rarely.  
• Any medication can cause a severe allergic reaction. Such reactions from a vaccine are very rare, estimated at about [ADDRESS_255559]/placenta after the baby [CONTACT_213072] t attached to it.  
 The Advisory Committee on Immunization Practices (ACIP) and the American College of 
Obstetricians & Gynecologists (ACOG ) recommend all women who will be pregnant  
during influenza season receive influenza vaccine. A  licensed, recommended, and age-
appropriate IIV or RIV4 may be used .
[ADDRESS_255560] -vaccination for assessment of local and systemic 
reactogenicity, solicited and unsolicited adverse events (AEs), serious AEs (SAEs), 
concomitant medication use, and unscheduled medical care. All participants will be 
monitored in a sitting or lying position for at least [ADDRESS_255561]  is registered on ClinicalTrials.gov  ([STUDY_ID_REMOVED]).  It is the  responsibility of 
the lead site for creating, maintaining, and uploading pertinent information regarding the 
study as required by 45 CFR 46.116(h)  to ClinicalTrials.gov .  The lead site will post their 
IRB-approved informed consent within the study’s recor d on ClinicalTrials.gov.   
Contributing sites will be responsible for providing the lead site with any changes to their 
site’s information as applicable.   
 
9.[ADDRESS_255562] be signed and dated by [CONTACT_213073].   
 
9.1.1  Vulnerable Subjects Research 
Vulnerable subjects  
This study proposes to include pregnant women and neonates.  
 
Pregnant women  
RIV4 and IIV4 are FDA licensed vaccines and are recommended by [CONTACT_213074] , however the risks for both vaccines are listed in section 8.3.   
 
The specific procedures to be performed as part of this study are limit ed to minimal 
blood draw (<  35mL over a 4 -week period), and other non -invasive proc edures that are 
commonly performed during routine physical exams and are considered safe for 
pregnant women.  These procedures do not pose greater than minimal risk to the fetus.  
 
This study will involve only those women who have given their free and inform ed 
consent in accordance with [ADDRESS_255563] of care.  The small amount of blood that will be drawn 
during the  duration of pregnancy (up to 30  ml) are considered safe and are not expected 
to cause any harm to the baby.   No inducement, monetary or otherwise, will be offered 
to terminate a pregnancy.  Individuals engaged in the research will have no part in any 
decisions as to the timing, method or procedures used to terminate a pregnancy, or in 
determining the viability of a neonate.   
 
Infants  
Identifiable private information will be collected about the infants at the time of delivery.   
Significant infant complications identified during the delivery visit will be followed up to 90 days of life.    
 
Mothers will be informed about the infant data collection at the time they consent for the 
study, and thus, the consent form for pregnant women will also serve as the parental permission for including the infant as a participant after delivery.   
 
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
33 REFERENCES  
1. Goodnight WH, Soper DE. Pneumonia in pregnancy. Crit Care Med 
2005;33:S390 -7. 
2. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza 
on acute cardiopulmonary hospi[INVESTIGATOR_96297]. Am J Epi[INVESTIGATOR_5541] 
1998;148:[ADDRESS_255564] P, Knight M, Ukoss. Perinatal 
outcomes after maternal 2009/H1N1 infection: national cohort study. BMJ 2011;342:d3214.  
4. Siston AM, Rasmussen SA, Honein MA, et al. Pandemic 2009 influenza A(H1N1) 
virus illness among pregnant women in the [LOCATION_002]. JAMA 2010;303:1517- 25. 
5. Committee on Obstetric P, Immunization Expert Work G, Centers for Disease C, 
Prevention's Advisory Committee on Immunization US, American College of O, Gynecologists. Committee opi[INVESTIGATOR_36851]. 608: influenza vaccination during pregnancy. 
Obstet Gynecol 2014;124:648- 51. 
6. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and Control of Seasonal 
Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization 
Practices - [LOCATION_002], 2017 -18 Influenza Season. MMWR Recomm Rep 2017;66:1-
20. 
7. Tamma PD, Ault KA, del Rio C, Steinhoff MC, Halsey NA, Omer SB. Safety of 
influenza vaccination during pregnancy. Am J Obstet Gynecol 2009;201:547- 52. 
8. Haberg SE, Trogstad L, Gunnes N, et al. Risk of fetal death after pandemic 
influenza virus infection or vaccination. The New England journal of medicine 2013;368:333 -40. 
9. Madhi SA, Cutland CL, Kuwanda L, et al. Influenza vaccination of pregnant 
women and protection of their infants. The New England journal of medi cine 
2014;371:918 -31. 
10. Nordin JD, Kharbanda EO, Vazquez Benitez G, et al. Maternal influenza vaccine 
and risks for preterm or small for gestational age birth. J Pediatr 2014;164:1051- 7 e2.  
11. Bratton KN, Wardle MT, Orenstein WA, Omer SB. Maternal influenza 
immunization and birth outcomes of stillbirth and spontaneous abortion: a systematic 
review and meta -analysis. Clin Infect Dis 2015;60:e11- 9. 
12. McMillan M, Porritt K, Kralik D, Costi L, Marshall H. Influenza vaccination during 
pregnancy: a systematic review of fetal death, spontaneous abortion, and congenital malformation safety outcomes. Vaccine 2015;33:2108- 17. 
13. Pandemic H. Influenza Plan. 2005.  
14. Vaccines Licensed for Use in the [LOCATION_002]. 2019. (Accessed 16Apr2019, 
2019, at 
https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.ht
m.) 
15. Skowronski DM, De Serres G. Role of Egg- adaptation Mutations in Low Infl uenza 
A(H3N2) Vaccine Effectiveness During the 2012- [ADDRESS_255565] Dis 
2018;67:[ADDRESS_255566] MK, Main EK, Currigan SM. Executive summary of the reVITALize 
initiative: standardizing obstetric data definitions. Obstetrics & Gynecology 
2014;124:150 -3. 
17. Statistics NCfH. 2019.  
18. Organization WH. Preterm birth. 2018. 
19. Influenza activity --[LOCATION_002] and worldwide, 2007- 08 season. MMWR Morb 
Mortal Wkly Rep 2008;57:692- 7. 
Safety of RIV4 versus IIV4 in Pregnancy   Version 4.0 
March 15, 2022  
 
34 20. Health UDo, Services H. Code of Federal Regulations, title 45, part 46. URL: 
http://www  hhs gov/ohrp/archive/humansubjects/guidance/45cfr46 html 2009.  
21. Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. 
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the 
Advisory Committee on Immunization Practices -[LOCATION_002], 2018- 19 Influenza 
Season. MMWR Recomm Rep 2018;67:1- 20. 
 